Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Hadji, P; Coleman, RE; Wilson, C; Powles, TJ; Clezardin, P; Aapro, M; Costa, L; Body, JJ; Markopoulos, C; Santini, D; Diel, I; Di Leo, A; Cameron, D; Dodwell, D; Smith, I; Gnant, M; Gray, R; Harbeck, N; Thurlimann, B; Untch, M; Cortes, J; Martin, M; Albert, US; Conte, PF; Ejlertsen, B; Bergh, J; Kaufmann, M; Holen, I.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

ANNALS OF ONCOLOGY. 2016; 27(3): 379-390 Nº de citas: 134 [doi:10.1093/annonc/mdv617]

Strasser-Weippl, K; Horick, N; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Boyle, F; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Rappold, E; Finkelstein, DM; Goss, PE.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

EUROPEAN JOURNAL OF CANCER. 2016; 56: 85-92 Nº de citas: 4 [doi:10.1016/j.ejca.2015.12.024]

Pereira, A; Perez-Medina, T; Magrina, JF; Magtibay, PM; Rodriguez-Tapia, A; Cuesta-Guardiola, T; Peregrin, I; Mendizabal, E; Lizarraga, S; Ortiz-Quintana, L.

"The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period"

SURGICAL ONCOLOGY-OXFORD. 2016; 25(1): 49-59 Nº de citas: 6 [doi:10.1016/j.suronc.2015.12.005]

Chan, A; Delaloge, S; Holmes, FA; Moy, B; Iwata, H; Harvey, VJ; Robert, NJ; Silovski, T; Gokmen, E; Von Minckwitz, G; Ejlertsen, B; Chia, SKL; Mansi, J; Barrios, CH; Gnant, M; Buyse, M; Gore, I; Smith, J; Harker, G; Masuda, N; Petrakova, K; Zotano, AG; Iannotti, ZN; Rodriguez, G; Tassone, P; Wong, A; Bryce, R; Ye, YN; Yao, B; Martin, M.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

LANCET ONCOLOGY. 2016; 17(3): 367-377 Nº de citas: 479 [doi:10.1016/S1470-2045(15)00551-3]

Reynes, G; Martinez-Sales, V; Vila, V; Balana, C; Perez-Segura, P; Vaz, MA; Benavides, M; Gallego, O; Palomero, I; Gil-Gil, M; Fleitas, T; Reche, E.

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

ANTI-CANCER DRUGS. 2016; 27(2): 133-137 Nº de citas: 11 [doi:10.1097/CAD.0000000000000314]

Martin, M; Brase, JC; Ruiz, A; Prat, A; Kronenwett, R; Calvo, L; Petry, C; Bernard, PS; Ruiz-Borrego, M; Weber, KE; Rodriguez, CA; Alvarez, IM; Segui, MA; Perou, CM; Casas, M; Carrasco, E; Caballero, R; Rodriguez-Lescure, A.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

BREAST CANCER RESEARCH AND TREATMENT. 2016; 156(1): 81-89 Nº de citas: 46 [doi:10.1007/s10549-016-3725-z]

Mesia, R; Vazquez, S; Grau, JJ; Garcia-Saenz, JA; Lozano, A; Garcia, C; Carles, J; Irigoyen, A; Manos, M; Garcia-Paredes, B; del Barco, E; Taberna, M; Escobar, Y; Cruz, JJ.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2016; 94(2): 289-296 Nº de citas: 24 [doi:10.1016/j.ijrobp.2015.10.019]

Masson-Lecomte, A; de Maturana, EL; Goddard, ME; Picornell, A; Rava, M; Gonzalez-Neira, A; Marquez, M; Carrato, A; Tardon, A; Lloreta, J; Garcia-Closas, M; Silverman, D; Rothman, N; Kogevinas, M; Allory, Y; Chanock, SJ; Real, FX; Malats, N; SBC EPICURO Study Investigators.

Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2016; 25(7): 1144-1150 Nº de citas: 4 [doi:10.1158/1055-9965.EPI-15-0894]

Lipton, A; Fizazi, K; Stopeck, AT; Henry, DH; Smith, MR; Shore, N; Martin, M; Vadhan-Raj, S; Brown, JE; Richardson, GE; Saad, F; Yardley, DA; Zhou, K; Balakumaran, A; Braun, A.

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

EUROPEAN JOURNAL OF CANCER. 2016; 53: 75-83 Nº de citas: 94 [doi:10.1016/j.ejca.2015.09.011]

Stopeck, AT; Fizazi, K; Body, JJ; Brown, JE; Carducci, M; Diel, I; Fujiwara, Y; Martin, M; Paterson, A; Tonkin, K; Shore, N; Sieber, P; Kueppers, F; Karsh, L; Yardley, D; Wang, H; Maniar, T; Arellano, J; Braun, A.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

SUPPORTIVE CARE IN CANCER. 2016; 24(1): 447-455 Nº de citas: 150 [doi:10.1007/s00520-015-2904-5]

De las Penas, R; Ponce, S; Henao, F; Herrero, CC; Carcereny, E; Alvarez, YE; Rodriguez, CA; Virizuela, JA; Lopez, RL.

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

SUPPORTIVE CARE IN CANCER. 2016; 24(1): 499-507 Nº de citas: 11 [doi:10.1007/s00520-015-2948-6]

Gonzalez-Martin, A; Alba, E; Ciruelos, E; Cortes, J; Llombart, A; Lluch, A; Andres, R; Alvarez, I; Aramenda, JM; de la Pena, FA; Barnadas, A; Batista, N; Calvo, L; Galve, E; Garcia-Palomo, A; Garcia-Saenz, JA; de la Haba, J; Lopez, R; Lopez-Vivanco, G; Martinez-Janez, N; de Duenas, EM; Plazaola, A; Rodriguez-Lescure, A; Ruiz, M; Sanchez-Rovira, P; Santaballa, A; Segui, MA; Tusquets, I; Zamora, P; Martin, M.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile

CURRENT CANCER DRUG TARGETS. 2016; 16(5): 415-428 Nº de citas: 13 [doi:10.2174/1568009615666150817121731]

Gayarre, J; Kamieniak, MM; Cazorla-Jimenez, A; Munoz-Repeto, I; Borrego, S; Garcia-Donas, J; Hernando, S; Robles-Diaz, L; Garcia-Bueno, JM; Cajal, TRY; Hernandez-Agudo, E; Soto, VH; Marquez-Rodas, I; Echarri, MJ; Lacambra-Calvet, C; Saez, R; Cusido, M; Redondo, A; Paz-Ares, L; Hardisson, D; Mendiola, M; Palacios, J; Benitez, J; Garcia, MJ.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients

Journal of Gynecologic Oncology. 2016; 27(1): Nº de citas: 22 [doi:10.3802/jgo.2016.27.e7]

Martinez, MT; Perez-Fidalgo, JA; Martin-Martorell, P; Cejalvo, JM; Pons, V; Bermejo, B; Martin, M; Albanell, J; Lluch, A.

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2016; 97: 96-106 Nº de citas: 48 [doi:10.1016/j.critrevonc.2015.08.011]

Llovet, P; Sastre, J; Ortega, JS; Bando, I; Ferrer, M; Garcia-Alfonso, P; Donnay, O; Carrato, A; Jimenez, A; Aranda, E; Leon, A; Gravalos, C; Camara, JC; Feliu, J; Sanchiz, B; Caldes, T; Diaz-Rubio, E.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

Molecular Diagnosis & Therapy. 2015; 19(6): 397-408 Nº de citas: 21 [doi:10.1007/s40291-015-0165-0]

Gavila, J; Lopez-Tarruella, S; Saura, C; Munoz, M; Oliveira, M; De la Cruz-Merino, L; Morales, S; Alvarez, I; Virizuela, JA; Martin, M.

SEOM clinical guidelines in metastatic breast cancer 2015

Clinical & Translational Oncology. 2015; 17(12): 946-955 Nº de citas: 24 [doi:10.1007/s12094-015-1476-7]

Aranda, E; Aparicio, J; Alonso, V; Garcia-Albeniz, X; Garcia-Alfonso, P; Salazar, R; Valladares, M; Vera, R; Vieitez, JM; Garcia-Carbonero, R.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

Clinical & Translational Oncology. 2015; 17(12): 972-981 Nº de citas: 28 [doi:10.1007/s12094-015-1434-4]

Berrocal, A; Arance, A; Espinosa, E; Castano, AG; Cao, MG; Larriba, JLG; Martin, JAL; Marquez, I; Soria, A; Algarra, SM.

SEOM guidelines for the management of Malignant Melanoma 2015

Clinical & Translational Oncology. 2015; 17(12): 1030-1035 Nº de citas: 6 [doi:10.1007/s12094-015-1450-4]